The Cansino laboratory wants to produce its anti-Covid-19 vaccine in Argentina

Authorities of the Chinese laboratory Cansino expressed their intention to produce their anti-Covid-19 vaccine in Argentina to supply the country and also all of Latin America, for which they began a dialogue process with the Government, and now they hope to define capacities, possibilities and needs. that enable the realization of the project.

The businessmen met with the Minister of Health, Carla Vizzottiwith the aim of highlighting the work carried out during the pandemic and addressing cooperation strategies for technology transfer.

“For us it is very important to value all the work that has been done so far. The pandemic has transformed the crisis into an opportunity and this table is a sign that we are taking advantage of that opportunity,” said Vizzotti.

The official explained that “this meeting is also to think about many strategies beyond Covid-19”and stressed the importance of working with the Cansino laboratory for technology transfer.

In this regard, he indicated that “it is very important to carry out a comprehensive approach in all axes with the Ministries of Health, Science, and Productive Development. That is why this issue is very important to us”, said the minister.

“There are many reasons why there is an interest in collaboration. We have technology that uses five different platforms, the research capacity, the professional team and we are prepared to develop the vaccines in a change in the pandemic”Hongyi Wang, Vice President of International Business at Cansino

Vizzotti announced that this Tuesday there will be a meeting with his peers from Science and Technology, Daniel Filmus, and Productive Development, Matías Kulfas, “to address a permanent work table with the aim of incorporating this issue and establishing roles for each one.”

“We are looking at options, exploring possibilities and looking for potential partners to be able to carry out this possibility of producing the anti-Covid-19 vaccine in Argentina,” the co-founder and executive director of Cansino Biologics, Xuefeng Yu, told Télam, who traveled to Buenos Aires with a delegation of executives from the Chinese company.

Yu pointed out that The initial idea is “to start with the anti-Covid vaccine”stressed that Cansino is “exploring other possibilities”, since the company has “a broad portfolio of vaccines”.

For his part, the executive vice president of the European subsidiary of Cansino, Pierre Morgon, a member of the delegation that came to Argentina, remarked that “it is the intention of the Argentine government” that the Chinese company produces vaccines in the country, “so so much is part of the conversations that are taking place”.

“We are in the embryonic phases of the project. It requires technology transfer and making a gradual transition with local manufacturers. It is a medium to long-term project,” Morgon told this agency.

The trade link between the two countries

The executive highlighted that the Chinese firm has “a relationship with Argentina, with the Cassará laboratory as a strategic partner”, with whom it carried out clinical trials during the pandemic.

“On this trip, the intention was to meet with people from the Ministries of Health, Science and Technology, and Productive Development to understand what the expectations are. This will allow us to articulate a plan according to expectations, needs and possibilities”, said the executive.

He pointed out that “the Argentine government has shown an interest, so it is good for us to start a dialogue on what the appropriate conditions are like to start collaborative work.”

“On Monday we had talks at the Ministry of Health, and this Tuesday there will be an interministerial meeting to decide the next steps to follow, how the production will be and how the collaboration will develop,” said Morgon, who stressed that “the The meeting last Monday with the Ministry of Health and with the National Immunization Commission was for a demonstration of interest from the Government, to see what vaccines are needed, what are the health requirements and the interests for local public health.

Thus, he stressed that “depending on interest, it will be possible to plan the development of vaccines.”

For his part, Cansino’s Vice President of International Business, Hongyi Wang, assured Télam that “there is a long-standing history with China”, and highlighted that “they are two countries that are very far away, but historically close”.

“There are many reasons why there is an interest in collaboration. We have technology that uses five different platforms, the research capacity, the professional team, and we are prepared to develop vaccines in a change in the pandemic,” the executive said.

–